Leadership Established in Zantac JCCP

The leadership panel in the Zantac litigation was recently established, including attorneys from six law firms. This panel of lawyers will help direct the litigation against makers of the antacid drug, that include Sanofi, GlaxoSmithKline, Boehringer Ingelheim and others. Plaintiffs claim that the active ingredient in Zantac may cause patients to develop certain types of cancers. Plaintiffs filing Zantac cancer lawsuits also allege that drug makers knew Zantac and its generic ranitidine contain unacceptable levels of the carcinogen N-nitrosodimethylamine (NDMA), but continued to market and sell the drug.

While most of the cases in the litigation were consolidated in a federal multi-district litigation (MDL) in the Southern District of Florida, many others were brought in California state court in Alameda County, under what is known as a Judicial Council Coordinated Proceeding (JCCP). The JCCP in California is currently handling over 60 complaints from more than 1,000 plaintiffs. Allegations are substantially similar among cases in the Zantac MDL and the JCCP.

Do you Think You Have a Valid Cancer Claim After Taking Zantac?

It’s not too late to investigate your potential Zantac cancer claim.